Recent News

• 04.22.2026 - CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
• 04.07.2026 - CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
• 03.19.2026 - CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
• 03.17.2026 - CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
• 03.12.2026 - CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
• 03.05.2026 - CervoMed to Participate in Upcoming Investor Conferences
• 03.04.2026 - CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
• 02.18.2026 - CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

Recent Filings

• 04.07.2026 - EX-99.1 EX-99.1
• 04.07.2026 - 8-K Current report
• 04.07.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.23.2026 - 8-K Current report
• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - 8-K Current report
• 03.17.2026 - EX-99.1 EX-99.1
• 03.17.2026 - 8-K Current report
• 03.13.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.04.2026 - 8-K Current report